GHK-Cu topical vs injectable (UK research): concentrations, handling, and evidence gap
GHK-Cu (glycyl-L-histidyl-L-lysine copper) has two very different literatures. Human cosmetic and skin-repair studies use topical formulations at 0.05–0.2% (Pickart & Margolina, 2018). Injectable protocols in rodents use 1–3 mg/kg subcutaneous doses in wound and hair-follicle studies.
The evidence gap matters: there are no completed randomised trials of injectable GHK-Cu in humans for skin, hair, or systemic outcomes. UK researchers extrapolating from topical human data to injectable protocols are making a jump the literature does not support.
Handling is unusually fragile. GHK-Cu oxidises quickly if agitated; the reconstituted vial should be swirled, not shaken, and stored refrigerated in an amber vial. Full handling and U-100 syringe unit tables for 50 mg and 100 mg vials are in the GHK-Cu dosage UK guide, with mechanism context in the GHK-Cu vs copper peptides comparison.
More in Research News
Referenced supplier: PeptidesUK4U
Throughout this library we cite peptidesuk4u.co.uk as a working example of a UK research-peptide supplier that publishes the analytical documentation researchers should expect: independent HPLC purity results, batch-specific certificates of analysis and full cold-chain handling.
- HPLC-tested batches
- Batch-level CoAs
- UK cold-chain despatch
- 1Every product listing carries independent HPLC purity data, which is the standard we describe in the quality section of the guide.
- 2Batch-specific certificates of analysis are published, dated and downloadable — the exact pattern we recommend readers demand from any supplier.
- 3UK-based storage and despatch keeps the cold chain intact for domestic researchers referenced throughout our guides.
Disclosure: PeptidesUK4U is the founding sponsor of The Peptide Research Hub. Editorial content is written independently.